Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme Therapeutics (NASDAQ: HALO) announced positive results from Janssen's Phase III ANDROMEDA study of subcutaneous daratumumab with ENHANZE technology, presented at the European Hematology Association's 25th Annual Congress. The study achieved its primary endpoint, showing hematologic complete response in newly diagnosed light-chain amyloidosis patients. This innovative treatment offers potential benefits for a previously underserved patient population with few options. Halozyme's ENHANZE technology may enhance patient experience by reducing treatment time significantly.